Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 June 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

C. difficile in 2011 is less severe with better outcomes than the infection in 2008

The latest issue of the American Journal of Gastroenterology compares the demographics, medication exposure, treatment patterns, and outcomes of patients with C. difficile in 2 different time periods.

News image

Over the past decade, the epidemiology of Clostridium difficile infection (CDI) has shown a remarkable increase in incidence with an associated increase in severity.

Dr Paul Feuerstadt and colleagues from Connecticut, USA compared the demographics, medication exposure, evaluation, treatment patterns, and outcomes of patients with CDI in 2 different time periods, including 2006–2008 and 2009–2011.

The researchers hypothesized that mortality is decreasing with increasing appropriateness of medical management.

The team retrospectively identified consecutive patients admitted to Montefiore Medical Center between 1/1/2006 and 12/31/2011 with symptomatic diarrhea, and a positive C. difficile toxin assay.

Factors associated with 30-day mortality include age, white blood cells, and albumin level
American Journal of Gastroenterology

The cohort was subdivided into those diagnosed in 2006–2008, and 2009–2011.

The research team obtained key parameters at the time of diagnosis including demographics, medication exposure, medical comorbidities, laboratory data, CDI evaluation, and various outcome measures.

The team created a subcohort for each time frame of patients diagnosed with severe CDI defined by white blood cell count >15,000 cells/μl, and albumin <3.0 g/dl and made the same comparisons as for the overall cohort.

The resesarch team identified 4 cohorts including CDI 2006–08, CDI 2009–11, severe CDI 2006–08, and severe CDI 2009–11.
 
CDI 09–11 patients were older and had higher Charlson comorbidity scores than did those in the CDI 06–08 cohort.

The team observed no significant demographic differences in the severe cohort.

For both the overall and severe cohorts, there was more macrolide exposure before diagnosis with CDI, and lower rates of quinolone exposure in the more recent era.

The researchers found that the disease process also appeared less severe in the CDI 2009–11 cohort with lower peak white blood cells during admission and at diagnosis.

Treatment patterns appeared more aggressive during the more recent time frame, with shorter durations of oral metronidazole, longer durations of IV metronidazole, more frequent use of vancomycin as the sole therapy, more frequent switching from metronidazole to vancomycin, and less frequent exposure to any metronidazole throughout treatment in the overall cohort.

The researchers found that the 30-day mortality decreased significantly in both the overall, and the severe cohorts from CDI 06–08 to CDI 09–11, with mortality decreasing significantly in the 8th and 9th decades of life in the overall cohort and in the 8th, 9th, and 10th decades in the severe cohort.

Dr Feuerstadt's team concludes, "In an urban United States population, CDI 2009–11 showed changes in medication exposures, less severe disease, and more aggressive management with better outcomes and decreased mortality compared with CDI 06–08."

"The most important factors associated with 30-day mortality in both an overall and severe CDI population include age, white blood cells, and albumin level at the time of diagnosis."

Am J Gastroenterol 2014; 109:1265–1276
18 August 2014

Go to top of page Email this page Email this page to a colleague

 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Statins and colorectal cancer in IBD
 24 June 2016 
Fibre for chronic idiopathic constipation
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 23 June 2016 
Touch screens in the IBD outpatient clinic
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Breath as a marker for IBS
 10 June 2016 
Rectal cancer surgery checklist
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Eosinophilic esophagitis
 03 June 2016 
Antibiotic prophylaxis in cirrhosis
 03 June 2016 
Mortality in hospitalized peptic ulcer patients
 03 June 2016 
Decision aid for surgical patients with ulcerative colitis
 02 June 2016 
Allergy tests for eosinophilic esophagitis
 02 June 2016 
Fatty liver disease and mortality
 02 June 2016 
Ethnic inequalities in rectal cancer care
 01 June 2016 
Predicting NASH resolution
 01 June 2016 
Predicting relapse in IBD
 01 June 2016 
Treatment of Hep C/HIV after liver transplant
 31 May 2016 
Markers as a reflection of inflammatory burden in ulcerative colitis
 31 May 2016 
Predicting Crohn's diseases before diagnosis
 31 May 2016 
Biomarker predicts post ERCP pancreatitis
 30 May 2016 
Challenges for direct-acting antivirals in Hep C
 30 May 2016 
Endoscopic indices for disease activity in ulcerative colitis
 30 May 2016 
Colonoscopy reimbursement reduction in practice

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us